Investors should avoid Teladoc and Recursion Pharmaceuticals as both companies grapple with declining revenue, stiff competition, and unproven business models in a challenging healthcare market.
Eli Lilly is incorporating AI into drug development with a strong pipeline of approved products.
Novo Nordisk is leveraging AI in drug development alongside its existing successful product lineup.
Bristol Myers Squibb is using AI to enhance drug development, though mentioned only briefly.
Teladoc Health and Recursion Pharmaceuticals remain high-risk investments as both companies struggle to prove their long-term viability. While Teladoc faces intense competition in the virtual therapy space, Recursion has yet to validate its AI-driven drug discovery model with any approved products.
Teladoc is struggling with declining revenue in its core BetterHelp segment and faces significant competition from platforms offering hybrid virtual and in-person care.
Unlike companies such as Eli Lilly or Novo Nordisk, which use AI to augment existing successful product pipelines, Recursion relies entirely on an unproven AI operating system without any currently approved drugs.